bluuebunny/crossref_metadata_2025_split huggingface dataset:
Almotriptan Malate
Authors: Cada Dennis J. , Levien Terri , Baker Danial E. 
Published: January 2018

Each month, subscribers to The Formulary® Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. The monographs are published in printed form and on diskettes that allow customization. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The October 2001 Formulary monograph topics are nesiritide, soledronic acid injection, anakinra, treprostinol sidium injection, and bosentan. The DUE is on nesiritide.
Nitroglycerin (Topical): Extravasation Treatment
Authors: Generali Joyce , Cada Dennis J. 
Published: January 2018

Off-Label Drug Uses This Hospital Pharmacy feature is extracted from Off-Label DrugFacts, a quarterly publication available from Facts and Comparisons. Off-Label DrugFacts is a practitioner-oriented resource for information about specific FDA-unapproved drug uses. This new guide to the literature will enable the health care professional/clinician to quickly identify published studies on off-label uses and to determine if a specific use is rational in a patient care scenario. The most relevant data are provided in tabular form so that the reader can easily identify the scope of information available. A summary of the data—including, background, study design, patient population, dosage information, therapy duration, results, safety, and therapeutic considerations—precedes each table of published studies. references direct the reader to the full literature for more
Do Not Give Hypodermic Syringes to Parents for Administering Oral Liquids to Children Report from Kansas City Gives Us Pause …
Authors: Cohen Michael R. 
Published: January 2018

These medication errors have occurred in health care facilities at least once. They will happen again—perhaps where you work. Through education and alertness of personnel and procedural safeguards, they can be avoided. You should consider publishing accounts of errors in your newsletters and/or presenting them in your inservice training programs. Your assistance is required to continue this feature. The reports described here were received through the USP Medication Errors Reporting Program, which is presented in cooperation with the Institute for Safe Medication Practices. If you have encountered medication errors and would like to report them, you may call USP toll-free, 24 hours a day, at 1-800-233-7767 (1-800-23-ERROR). Any reports published by ISMP will be anonymous. Comments are also invited; the writers' names will be published if desired. ISMP may be contacted at the address shown below.
Stability of Ciprofloxacin and Vancomycin Hydrochloride in AutoDose Infusion System Bags
Authors: Trissel Lawrence A. , Xu Quanyun A. , Zhang Yanping , Saenz Christopher A. , Ingram Delshalonda S. 
Published: January 2018

The objective of this study was to evaluate the physical and chemical stability of ciprofloxacin 400 mg/100 mL and vancomycin as the hydrochloride 1 g/100 mL each admixed in 0.9% sodium chloride injection packaged in AutoDose Infusion System bags. Triplicate test samples were prepared by admixing the necessary amount of each antibiotic with a portion of 0.9% sodium chloride injection and bringing the admixture of each drug to a final volume of 100 mL with additional 0.9% sodium chloride injection. The test solutions were packaged in ethylene vinyl acetate (EVA) plastic containers (AutoDose dags) designed for use in the AutoDose Infusion System. Samples were protected from light and evaluated at appropriate intervals for up to 7 days at 23°C and up to 30 days at 4°C. Physical stability was assessed using a multistep evaluation procedure that included turbidimetric and particulate measurement as well as visual inspection. Chemical stability was assessed using stability-indicating HPLC analytical techniques based on the determination of drug concentrations initially and at appropriate intervals over the study periods. The admixtures were clear and colorless when viewed in normal fluorescent room light and with a Tyndall beam. Measured turbidity and particulate content were low and exhibited little change. HPLC analysis found that both ciprofloxacin and vancomycin hydrochloride remained stable for 30 days at 4°C and 7 days at 23°C. Both ciprofloxacin and vancomycin hydrochloride exhibited physical and chemical stability consistent with previous studies on these drugs. The AutoDose Infusion System bags were not found to affect adversely the physical and chemical stability of these antibiotics.
Crotalidae Polyvalent Immune Fab (Ovine)
Authors: Cada Dennis J. , Levien Terri , Baker Danial E. 
Published: January 2018

Each month, subscribers to The Formulary® Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. The monographs are published in printed form and on diskettes that allow customization. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The October 2001 Formulary monograph topics are darbepoetin alfa, alteplase for CVAD clearance, cefditoren pivoxil, digox-in immune fab, and teriparatide injection. The DUE is on darbepoetin alfa.
Zoledronic Acid for Injection
Authors: Cada Dennis J. , Levien Terri , Baker Danial E. 
Published: January 2018

Each month, subscribers to The Formulary® Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. The monographs are published in printed form and on diskettes that allow customization. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The December 2001 Formulary monograph topics are budesonide modified-release capsules, tenofovir disoproxil fumarate, pegfilgrastim, fulvestrant, and etonogestrol/ethinyl estradiol vaginal ring. The DUE is on budesonide modified-release capsules.
Another Purpose for “Purpose” Look-Alike Unit-Dose Containers Mixed up Misinterpretation of Sliding-Scale Insulin Dose
Authors: Cohen Michael R. 
Published: January 2018

These medication errors have occurred in health care facilities at least once. They will happen again—perhaps where you work. Through education and alertness of personnel and procedural safeguards, they can be avoided. You should consider publishing accounts of errors in your newsletters and/or presenting them in your inservice training programs. Your assistance is required to continue this feature. The reports described here were received through the USP Medication Errors Reporting Program, which is presented in cooperation with the Institute for Safe Medication Practices. If you have encountered medication errors and would like to report them, you may call USP toll-free, 24 hours a day, at 1-800-233-7767 (1-800-23-ERROR). Any reports published by ISMP will be anonymous. Comments are also invited; the writers' names will be published if desired. ISMP may be contacted at the address shown below.
Action Needed to Prevent Dangerous Zyrtec–Zyprexa Mix-Ups Preventing Parenteral Line Mix-Ups ADD-Vantage Bags are Latex-Free but Vials may Not be
Authors: Cohen Michael R. 
Published: January 2018

These medication errors have occurred in health care facilities at least once. They will happen again—perhaps where you work. Through education and alertness of personnel and procedural safeguards, they can be avoided. You should consider publishing accounts of errors in your newsletters and/or presenting them in your inservice training programs. Your assistance is required to continue this feature. The reports described here were received through the USP Medication Errors Reporting Program, which is presented in cooperation with the Institute for Safe Medication Practices. If you have encountered medication errors and would like to report them, you may call USP toll-free, 24 hours a day, at 1-800-233-7767 (1-800-23-ERROR). Any reports published by ISMP will be anonymous. Comments are also invited; the writers' names will be published if desired. ISMP may be contacted at the address shown below.
Preventing Medication Errors with a “Pharmacy Admission Note” for HIV-Positive Patients
Authors: Segarra-Newnham Marisel 
Published: January 2018

Purpose To describe the utility of a clinical pharmacist's evaluation of HIV-positive patients upon hospital admission. Methods At our Veterans Affairs Medical Center, HIV-positive patients are assigned to the Infectious Diseases (ID) team for clinical follow-up. Since March of 1999, however, general medicine staff admit HIV-positive patients to the facility. To decrease possible medication errors, communicate medication regimens, and provide continuity of care, the ID clinical pharmacist writes a “Pharmacy Admission Note” for each HIV-positive patient. A 2-year retrospective review of these notes was conducted. Results Fifty-one patients were admitted during the study period. The ID clinical pharmacist provided 317 recommendations (median 4.2 per patient). One hundred seventy-three recommendations were intended to avoid medication errors (55%). The most common potential errors were “medication no longer needed” (n = 65, 38%) and “decrease dose” (n = 50, 29%). Conclusions The use of a Pharmacy Admission Note facilitates communication with the admitting teams, provides continuity of care, and prevents medication errors.
Patient Drug Information Handouts: Finding the Source that Best Fits Your Organization's Needs
Authors: Sommers Sunshine D. 
Published: January 2018

Objective To systematically compare patient drug information handout sources and make an informed decision about which handouts to give patients in a health maintenance organization. Methods Desirable patient handout structure and content elements were identified. Known drug information sources were listed and an Internet search was performed to locate additional sources. Products were scored according to the extent that they contained the desirable elements. Results Eight patient drug information sources were evaluated. These sources were the American Society of Health System Pharmacists, Clinical Reference Systems, First Data Bank, Gold Standard Multimedia, Lexi-comp, Micromedex, Mosby, and Multum. The maximum possible score was 75. Lexi-Comp received the highest score (67). Gold Standard Media had the second highest score (63). Conclusions: Lexi-Comp's product was found to have the best overall structure and content. The scoring system used was based on what the author deemed important and could be altered to reflect different values (eg, items could be weighted differently based on their relative importance).
Darbepoetin Alfa
Authors: Cada Dennis J. , Levien Terri , Baker Danial E. 
Published: January 2018

Each month, subscribers to The Formulary® Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. The monographs are published in printed form and on diskettes that allow customization. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The December 2001 Formulary monograph topics are budesonide modified-release capsules, tenofovir disoproxil fumarate, pegfilgrastim, fulvestrant, and etonogestrol/ethinyl estradiol vaginal ring. The DUE is on budesonide modified-release capsules.
• Caution Advised When Preservative-Free Forms of Midazolam are Used • New FDA Panel • Don't Overlook Preanalytical Variables When Assessing Lab Results • Errors in Clinical References • Another Fatality Due to Unsafe Pharmacy Practice
Authors: Cohen Michael R. 
Published: January 2018

These medication errors have occurred in health care facilities at least once. They will happen again—perhaps where you work. Through education and alertness of personnel and procedural safeguards, they can be avoided. You should consider publishing accounts of errors in your newsletters and/or presenting them in your inservice training programs. Your assistance is required to continue this feature. The reports described here were received through the USP Medication Errors Reporting Program, which is presented in cooperation with the Institute for Safe Medication Practices. If you have encountered medication errors and would like to report them, you may call USP toll-free, 24 hours a day, at 800-233-7767 (800-23-ERROR). Any reports published by ISMP will be anonymous. Comments are also invited; the writers' names will be published if desired. ISMP may be contacted at the address shown below.
Herbal Supplement Use among Patients in a Rural Health System
Authors: Gore Alvin , Mills Orlando , Gonzalez Luis , Volokhonsky Helen 
Published: January 2018

Background The use of herbal supplements is common but has not been adequately documented in a rural health system. Methods A questionnaire measuring the use of herbal supplements, disclosure to a physician, and discussion with a physician was distributed to 400 adult patients in three rural offices. A separate survey was distributed to 24 physicians in these three practices. Results Two hundred ninety-three of 400 patient questionnaires (74%) and 18 of 22 physician questionnaires (75%) were returned and analyzed. Twenty percent of patients used herbal supplements and 59% of these disclosed this use to their physicians. Only half of the doctors returning the survey regularly asked their patients about herbal use and most admitted a lack of knowledge about herbals. Conclusion The use of herbal products may be less common in a rural health system than in other practice settings. Patients would disclose the use of herbal supplements to physicians more often if they were asked about such consumption and physician knowledge about the products were improved.
Clinicians Often Unaware of Colchicine Dose Limits; What is a “Bolus?”; Drug Information Leaflets can Help Prevent Errors
Authors: Cohen Michael R. 
Published: January 2018

These medication errors have occurred in health care facilities at least once. They will happen again—perhaps where you work. Through education and alertness of personnel and procedural safeguards, they can be avoided. You should consider publishing accounts of errors in your newsletters and/or presenting them in your inservice training programs. Your assistance is required to continue this feature. The reports described here were received through the USP Medication Errors Reporting Program, which is presented in cooperation with the Institute for Safe Medication Practices. If you have encountered medication errors and would like to report them, you may call USP toll-free, 24 hours a day, at 800-233-7767 (800-23-ERROR). Any reports published by ISMP will be anonymous. Comments are also invited; the writers' names will be published if desired. ISMP may be contacted at the address shown below.
The Effect of the Bispectral Index on Medication Utilization in the Operating Room and Time to Discharge from the Postanesthesia Care Unit
Authors: Windisch Paul A. , Worsham G. Michael 
Published: January 2018

Goal To assess the effectiveness of the Bispectral Index (BIS) monitor in reducing hypnotic medication utilization, associated costs, and length of patient stay in the postanesthesia care unit (PACU). Methods The utilization and cost of inhaled anesthetics, induction agents, and time to discharge from the PACU before the introduction of BIS technology were evaluated retrospectively. The same data was then collected from patients whose level of consciousness was assessed using the BIS monitor. Results The mean total medication cost per patient case was $53.40 in the baseline group compared with $33.10 in the BIS group; when normalized to a 60-minute case, total costs per case were comparable. The mean cost of inhaled anesthetic per case in the baseline group was $19.47 compared with $8.14 in the BIS group; the normalized cost of inhaled anesthetic per case in the baseline group was $13.43 compared with $9.36 in the BIS group. The mean time to discharge from the recovery room was 68 minutes in the baseline group and 54 minutes in the BIS group. Cases were also categorized by length of procedure, and costs and times to discharge were tabulated for each category. Conclusion The BIS monitor appears to decrease the utilization and costs of hypnotic/induction agents. However, the cost of the BIS monitor is substantial and could ultimately offset the medication cost savings.
Frovatriptan Succinate
Authors: Cada Dennis J. , Levien Terri , Baker Danial E. 
Published: January 2018

Each month, subscribers to The Formulary® Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-ser-vices. A comprehensive target drug utilization evaluation (DUE) is also provided each month. The monographs are published in printed form and on diskettes that allow customization. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The April 2002 Formulary monograph topics are pegfilgrastim, fondaparinux sodium, dutasteride, aripiprazole, and ezetimibe. The DUE is on drotrecogin alfa.
FDA Advise-ERR: Deaths Associated with IV Colchicine; PCA Means Patient-Controlled Analgesia
Authors: Cohen Michael R. 
Published: January 2018

These medication errors have occurred in health care facilities at least once. They will happen again—perhaps where you work. Through education and alertness of personnel and procedural safeguards, they can be avoided. You should consider publishing accounts of errors in your newsletters and/or presenting them in your inservice training programs. Your assistance is required to continue this feature. The reports described here were received through the USP Medication Errors Reporting Program, which is presented in cooperation with the Institute for Safe Medication Practices. If you have encountered medication errors and would like to report them, you may call USP toll-free, 24 hours a day, at 800-233-7767 (800-23-ERROR). Any reports published by ISMP will be anonymous. Comments are also invited; the writers' names will be published if desired. ISMP may be contacted at the address shown below.
Selecting Appropriate Pharmacotherapy for Patients with Osteoporosis: Holistic Risk—Benefit Analysis
Authors: Hansten Philip D. 
Published: January 2018

In the US, the major pharmacotherapeutic approaches for the prevention or treatment of osteoporosis in women are estrogen-based hormone replacement therapy, selective estrogen receptor modulators, salmon calcitonin, bisphosphonates, calcium, and vitamin D. All of these treatments are beneficial in increasing bone mineral density and reducing fractures in patients with osteoporosis. However, each of the therapies possesses a unique mechanism of action and other potential benefits and side effects. Estrogen replacement therapy may lower the risk of cardiovascular disease, but it increases the risk of venous thromboembolism (VTE) and may increase the risk of breast cancer. Unopposed estrogen therapy is associated with increased risk for endometrial cancer, but the addition of progestins virtually eliminates this adverse event. The selective estrogen receptor modulator raloxifene is associated with positive cardiovascular effects and demonstrates a protective effect against some types of breast cancer. Like estrogen, raloxifene increases the risk of VTE. Salmon calcitonin has a strong analgesic effect and is not associated with any serious long-term adverse events, but some individuals may not be able to tolerate the nasal formulation. Bisphosphonates are associated with serious upper GI effects. The concomitant administration of calcium and vitamin D in all patients being treated for osteoporosis is generally recommended. Selecting optimal treatment relies on an individualized risk–benefit analysis that takes into account the patient's medical history, concomitant diseases, current medications, general physical and mental well being, and personal feelings about the various therapies. Careful consideration of the various treatment options may lead to improved compliance and more effective management of osteoporosis.